Roche-Hansoh deal illustrates China’s growing role as source of new drugs
By Steve Scherer ( October 20, 2026, 18:12 GMT | Comment) -- Roche’s pact with Hansoh underscores China’s growing importance in supplying experimental medicines, supported by rapid development and greater trust in its science. Hansoh will receive $400 million upfront and $110 million after a year, with more than $15 billion in possible milestones, although experts said licensing growth could ease.Roche’s latest agreement with Hansoh Pharmaceutical highlights how faster early development and growing confidence in Chinese research have turned China into a major source of drug candidates for global pharmaceutical companies, even as dealmakers see scope for the licensing boom to moderate in coming years....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.